TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05414721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low flow desflurane anesthesia (Group D)
Description: When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
Study: NCT05454137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared medical appointment
Description: Shared medical appointment
Study: NCT04594603

Intervention type: OTHER
Intervention: Phacoemulsification for cataract
Description: Phacoemulsification for removal of cataract

Intervention type: OTHER
Intervention: Phacoemulsification for cataract
Description: Phacoemulsification for removal of cataract
Study: NCT05472181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (Repetitive TMS)
Description: TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech training
Description: The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech training
Description: The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
Study: NCT05240924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.

Intervention type: OTHER
Group type: OTHER
Intervention: Stress Management Training
Description: The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
Study: NCT06500000

Intervention type: DIAGNOSTIC_TEST
Intervention: liquid chromatography-mass spectrometry (LC/MS)
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.

Intervention type: DIAGNOSTIC_TEST
Intervention: liquid chromatography-mass spectrometry (LC/MS)
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.

Intervention type: DIAGNOSTIC_TEST
Intervention: liquid chromatography-mass spectrometry (LC/MS)
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
Study: NCT06570239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervention group
Description: Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks.
Study: NCT05186181

Intervention type: BEHAVIORAL
Intervention: In situ fenestration
Description: Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
Study: NCT05878366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT
Description: Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT
Description: SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT
Description: SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
Study: NCT05131178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q Pump® with continuous infusion of bupivacaine
Description: 270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ON-Q Pump® with continuous infusion of saline
Description: 270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
Study: NCT05652374

Intervention type: DEVICE
Group type: OTHER
Intervention: Ialuril 50ml Prefill
Description: 50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months

Intervention type: DEVICE
Group type: OTHER
Intervention: Ialuril 50ml Prefill
Description: 50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrofurantoin
Description: nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrofurantoin
Description: nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
Study: NCT04742465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.
Description: Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion.
Study: NCT05022004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide ophthalmic suspension
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt®
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Study: NCT05892783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual treatment
Description: soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
Study: NCT06098807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Centered Treatment for Problematic Gaming and Excessive Screen Use
Description: Based on earlier implementation research with parents and children the treatment is likely to consist of a low number of sessions ;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
Study: NCT05780853

Intervention type: DIAGNOSTIC_TEST
Intervention: Tablet Game-based Assessment - YARN assessment service
Description: Tablet game-based assessment to assess neurodevelopmental profile.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tablet Game-based Assessment - YARN assessment service
Description: Tablet game-based assessment to assess neurodevelopmental profile.

Intervention type: DIAGNOSTIC_TEST
Intervention: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
Description: A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.

Intervention type: DIAGNOSTIC_TEST
Intervention: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
Description: A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.

Intervention type: OTHER
Intervention: Demographic questionnaire
Description: Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.

Intervention type: OTHER
Intervention: Demographic questionnaire
Description: Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
Study: NCT04614545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 37.5 Mg
Description: Patients will receive 37.5 mg of phentermine daily for a 12 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 Mg
Description: Patients will receive 37.5 mg of phentermine daily for a 12 week duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary program
Description: Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary program
Description: Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Patients will be provided with a personalized exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Patients will be provided with a personalized exercise program
Study: NCT05641831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT05736887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in 600mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 600mg tablets
Study: NCT05641831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05930951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBT076
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBT076
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
Study: NCT05489861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-AM
Description: To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F-AM
Description: To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
Study: NCT05227690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231 10 mg
Description: CVL-231 10 mg, oral (tablet), once per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Required CVL-231 30 mg
Description: CVL-231 30 mg, oral (tablet), once per day for 6 weeks
Study: NCT04614662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK Symptom Screening Linked to Feedback to Providers
Description: Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
Study: NCT05474859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XT-0528
Description: Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XT-0528
Description: Once Daily
Study: NCT05227690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study: NCT05880862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
Study: NCT05474859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XT-0528
Description: Once Daily
Study: NCT05880862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Chloride
Description: A 12-week course of Trospium XL -extended release, 60mg once daily.
Study: NCT05436938

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use
Study: NCT05606354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Experimental

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Experimental
Study: NCT05462613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection